ArticleJapanese journal of ophthalmology2020
Baerveldt glaucoma drainage implant surgery for secondary glaucoma in patients with transthyretin-related familial amyloid polyneuropathy.
Article in Japanese journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study.Eye (London, England) · 2025Article
- Long-term surgical results of trabeculectomy for secondary glaucoma in Val30Met hereditary transthyretin amyloidosis.Scientific reports · 2023Article
- Modified Technique of Ex-PRESSClinical ophthalmology (Auckland, N.Z.) · 2023Article
- Suture trabeculotomy ab interno for secondary glaucoma in Japanese patients with Val30Met hereditary transthyretin amyloidosis.Scientific reports · 2022Article
- Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise.International journal of ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate outcomes associated with Baerveldt glaucoma drainage implant (BGI) surgery for refractory glaucoma secondary to transthyretin (TTR)-related familial amyloid polyneuropathy (FAP) with TTR Val30Met mutation. STUDY
designRetrospective case series.
methodsMedical records of 5 eyes of 4 patients were reviewed. All patients had refractory glaucoma secondary to FAP with a history of unsuccessful intraocular pressure (IOP) control by trabeculectomy with mitomycin C, underwent BGI surgery, and were followed up for at least 1 year. The primary outcome was mean postoperative IOP, and secondary outcomes included the number of ocular hypotensive medications and postoperative complications.
resultsThe mean postoperative follow-up period was 52.4 months. The mean preoperative IOP of 37.0 mmHg was reduced to 13.4 mmHg immediately postoperatively, and respective subsequent means were 15.8, 13.0, 14.4, and 16.8 mmHg at 1, 3, 6, 12, and 24 months (P < 0.05). The preoperative mean number of ocular hypotensive medications of 5.4 was reduced to respective means of 2.2, 1.6, 2.8, 2.8, and 2.8 at 1, 3, 6, 12, and 24 months. One eye suffered from IOP elevation and underwent cyclophotocoagulation at 26 months. Another was dropped from further analyses because of deterioration in the patient's general condition due to FAP progression. The remaining 3 eyes exhibited adequate IOP control (13, 13, 13 mmHg) at the final visit.
conclusionBGI surgery may be the current optimal treatment for patients with refractory glaucoma secondary to TTR-FAP with regard to achieving long-term IOP reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.